Every company that goes public gets covered.
Including yours.

Names 33 rivals across three markets — launch, satellite broadband and direct-to-cell. Breadth, not a single named nemesis: the field is wide, and named once each.

A sustainability-focused commercial bank IPO'ing into a 22-name crossfire — traditional banks (Truist, BMO, KeyBank, Live Oak), digital banks (SoFi, LendingClub), private-credit funds (Blue Owl, Ares) and fintechs (Chime, Revolut) all named as rivals.

Pioneering a drug for the 'undruggable' β-catenin/TCF target in the Wnt pathway. Because zolucatetide is first-of-its-kind, the filing names only a few indirect rivals in the adjacent γ-secretase field — Merck KGaA's Ogsiveo, SpringWorks and Immunome. A $670M raise on a novel mechanism; no revenue yet.

The quantum leader fights on two fronts: Big Tech — IBM, Alphabet, Microsoft, Amazon — named as product competitors, and the pure-play field — IonQ, Rigetti, QuEra, Atom, PsiQuantum — listed as peers. A $1.68B raise on trapped-ion technology still years from broad commercial scale, with Honeywell — its 2021 co-founder — still holding ~47.8% of the vote.

A defense-technology prime contractor (~$433M revenue) IPO'ing into the autonomous-warfare race — naming legacy primes RTX, Lockheed Martin and Elbit alongside drone-era challengers Anduril, UVision, Black Sea Technologies and Sea Machines.

Lists Google, Meta and Amazon as rivals — then names them again as the platforms it depends on. A Blackstone-controlled ad-tech platform boxed in by the same walled gardens it competes with.

A global M&A advisory firm going public into a crowded boutique field — it names 11 direct rivals, from Houlihan Lokey and Jefferies to Lazard, Moelis and Rothschild, while staking out the private-capital-markets niche.

Names the whole compute establishment — chipmakers NVIDIA, AMD and Intel, plus the AWS, Azure, Google Cloud and Oracle clouds it sells through and competes against. NVIDIA alone appears 25 times. Profitable in 2025 — but two customers, MBZUAI (62%) and G42 (24%), drove 86% of revenue, and insiders keep ~99.2% of the vote.

A pre-revenue enhanced-geothermal developer raising ~$1.89B at $27 — reporting just $138K of ancillary fees against a $57.8M net loss. It names only five small geothermal peers, while founders keep ~53% of the vote via 40-vote Class B shares.

Its lead RIPK2 inhibitor (OD-001) faces a two-layer field: a pack of RIPK2 developers — GSK, Novartis, BMS, plus startups like Vibliome and Accro — and, in IBD, the marketed establishment: AbbVie's Humira/Skyrizi/Rinvoq, J&J's Stelara, Lilly's Omvoh, Takeda's Entyvio. 14 named rivals; no revenue yet.

Its lead drug GlyphAllo is an oral allopregnanolone prodrug — putting it head-to-head with Sage Therapeutics (same molecule class, named 7×), plus the marketed depression field: J&J's Caplyta and Spravato, AbbVie's Vraylar, Axsome's Auvelity, Otsuka's Rexulti. Founded by the Karuna Therapeutics team. No revenue yet.

Reformulates the two approved IPF drugs as inhaled versions — so it competes head-on with the makers of Ofev (Boehringer Ingelheim) and Esbriet (Roche/Genentech) using their own molecules, against a pipeline of a dozen more. Clinical-stage, no revenue; a $300M raise.

Its NULISA platform and ARGO instruments take on just two named rivals in ultra-sensitive proteomics — Olink (now owned by Thermo Fisher), referenced 24 times, and Quanterix. Revenue tripled to $74.2M, up 195%.

A Bain Capital- and Qatar-backed obesity challenger whose lead drug is in-licensed from China's Hengrui — taking on the GLP-1 duopoly. The S-1 names a dozen rivals, led by Eli Lilly (Zepbound) and Novo Nordisk (Wegovy). No revenue yet; a $625M war chest.

A global air-quality and HVAC manufacturer raising ~$2.23B — it names 20 rivals across its segments: AAON, Trane and Greenheck in air handling, Vertiv and Munters in data-center cooling, Panasonic and Bosch in residential ventilation.

A drilling-equipment manufacturer (~$822M revenue) spun out of Baker Hughes and Akastor — and still controlled by them via dual-class shares. It names NOV (11×) and Schlumberger as its primary rivals, plus a fragmented field of regional and Chinese-based manufacturers.